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Short Communication
A short-term increase in cancer risk associated with daytime
napping is likely to reflect pre-clinical disease: prospective
cohort study
BJ Cairns*,1, RC Travis1, X-S Wang1, GK Reeves1, J Green1 and V Beral1 on behalf of the Million Women Study
Collaborators1,2
1Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UK
BACKGROUND: Sleep disturbance, a correlate of which is daytime napping, has been hypothesised to be associated with risk of breast
and other cancers.
METHODS: We estimated relative risks (RR) of breast and other invasive cancers by the reported frequency of daytime napping in a
large prospective cohort of middle-aged women in the UK.
RESULTS: During an average of 7.4 years of follow-up, 20 058 breast cancers and 31 856 other cancers were diagnosed. Over the first 4
years of follow-up, daytime napping (sometimes/usually vs rarely/never) was associated with slightly increased risks of breast cancer
(RR¼ 1.10, 95% CI 1.06–1.15) and of other cancers (RR¼ 1.12, 1.08–1.15), but the RRs decreased significantly with increasing follow-
up time (P¼ 0.001 and P¼ 0.01, respectively, for trend). Four or more years after baseline, there was no elevated risk of breast
cancer (RR¼ 1.00, 0.96–1.05), and only marginally greater risk of other cancers (RR¼ 1.04, 1.01–1.07).
CONCLUSION: The effect of pre-clinical disease is a likely explanation for the short-term increased risk of breast and other cancers
associated with daytime napping.
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Concern about possible increased risks for cancer associated with
night work, circadian rhythm disruption, and impaired nocturnal
melatonin production (Cohen et al, 1978; Stevens, 1987;
Erren, 2002; Stevens, 2002; Straif et al, 2007; Wang et al, 2011)
has prompted interest in cancer risk in relation to sleep behaviours
and disturbance. Several studies have examined associations
between sleep duration and breast cancer risk (Verkasalo et al,
2005; McElroy et al, 2006; Pinheiro et al, 2006; Kakizaki et al, 2008;
Wu et al, 2008), but have not demonstrated a consistent
association. Daytime fatigue and daytime napping are associated
with sleep disturbance (Ursin et al, 2005), and cancer risk
might therefore be related to daytime napping. Although there is
a substantial literature on sleep problems and fatigue in
cancer patients (Davidson et al, 2002; Stasi et al, 2003; Lee et al,
2004), including before treatment (Ancoli-Israel et al, 2006),
little has been published on whether daytime napping is a marker
of pre-clinical disease. The association between daytime napping
and cancer mortality has been examined in two cohorts (Suzuki,
2007; Stone et al, 2009; Tanabe et al, 2010); one found increased
liver cancer mortality among women who nap during the day
(Suzuki, 2007). This is the first prospective study to investigate the
association between daytime napping and cancer incidence.
MATERIALS AND METHODS
The Million Women Study, a population-based prospective cohort
study, has been described in detail elsewhere (The Million Women
Study Collaborative Group, 2003). Briefly, during 1996–2001 B1.3
million women were recruited through the UK National Breast
Screening Programme for a study of women’s health, initially
investigating breast cancer risk in relation to use of hormone therapies
for the menopause. Ethical approval for the study was provided by the
Oxford and Anglia Multi-Centre Research Ethics Committee.
Baseline for these analyses was B3 years after recruitment,
when participants were invited to complete a second study
questionnaire (1999–2005; see http://www.millionwomenstudy.org)
with questions on a range of health and lifestyle factors,
including: ‘Do you have a nap during the day?’, with possible
responses ‘rarely/never’, ‘sometimes’, and ‘usually’. Data on
incident cancers during the follow-up period, coded according to
the International Classification of Diseases, 10th Revision (ICD-10;
World Health Organisation, 1992), are routinely provided for all
participants by the National Health Service Central Registers. For
this analysis we examined risks of all malignancies combined
(ICD-10 C00–C97) and risks of cancers at 17 of the most common
sites, particularly breast cancer (ICD-10 C50). Women were
excluded from all analyses if they had a previous cancer or
missing data on daytime napping at baseline. For analyses of
endometrial cancer, women were also excluded if they reported a
hysterectomy before baseline, or had unknown hysterectomy
status; for analyses of ovarian cancer, women were also excluded if
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they reported a bilateral oophorectomy before baseline, or had
unknown oophorectomy status.
Repeat assessments of daytime napping behaviours were
available for some participants, and were used to assess repeat-
ability of reported napping behaviours over time. A small
proportion of participants completed the baseline study
questionnaire twice, with 1.7 years on average between first and
repeat responses. The same question was also asked of all
participants 4.5 years later, on average (most during 2006–2007),
with possible responses ‘rarely/never’, ‘sometimes’, ‘usually’, and
‘most of the time’; the latter two responses were combined to
assess agreement with baseline data. Baseline and repeat responses
were compared using Cohen’s kappa statistic for agreement
(Cohen, 1960) and Spearman’s rank correlation coefficient.
Relative risks (RR) were estimated by categories of daytime
napping at baseline using Cox regression, with minimal adjust-
ment by stratification for age at and region of recruitment, and
further adjustment for health and lifestyle covariates, as described
below. Analyses were conducted either over the full period of
follow-up for incident cancer, or, to investigate napping as a
possible marker of pre-clinical disease, after dividing follow-up
time from baseline into approximately equal intervals (2-year
periods, 0–1.9, 2–3.9, 4–5.9, andX6 years, or 4-year periods, 0–3.9
and X4 years). Tests for trends in RRs with increasing follow-up
time were conducted by inverse-variance weighted least squares
regression of the log RRs against the average time at risk in each
2-year follow-up period. All statistical tests were two-sided. All
analyses were performed using the Stata version 12.0 (StataCorp,
College Station, TX, USA).
RESULTS
In total, 795 238 women aged 50–64 years at recruitment were
included in these analyses, with 7.4 years of follow-up per women on
average (Supplementary Table 1). During this period, 51 914 incident
invasive cancers were diagnosed, including 20058 breast cancers.
Women who reported that they napped either sometimes or usually
were older and (after adjustment for age) slept longer on average
over a 24-h period than women who reported napping rarely/never;
they were more likely to be of lower socioeconomic status, to smoke,
and to use menopausal hormone therapy, had a higher body mass
index and lower alcohol consumption, and were less likely to engage
in strenuous physical activity or be in paid employment. Almost all
women were postmenopausal at baseline.
After exploring effects of potential confounders, we adopted a
multivariable model for subsequent analyses of RRs in relation to
daytime napping at baseline, adjusting for age at recruitment,
region of residence, smoking status, body mass index, sleep
duration, use of menopausal hormone therapy, socioeconomic
status, strenuous physical activity, and alcohol consumption
(see Supplementary Table 2 for results and covariate definitions).
Repeat self-reports of napping behaviour from 15 235 women,
provided 1.7 years on average after baseline, showed good
agreement with baseline data (percentage agreement¼ 79%,
Cohen’s kappa¼ 0.61; Spearman’s correlation¼ 0.69). There was
similar, moderately good agreement of daytime napping reported
at baseline with that reported 4.5 years later, on average,
among 531 633 women (percentage agreement¼ 74%; Cohen’s
kappa¼ 0.51; Spearman’s correlation¼ 0.61).
Overall, daytime napping at baseline was associated with a small
increase in total cancer risk during follow-up. Under the multivariable
model described above, the adjusted RRs of any cancer were 1.06 (95%
CI 1.04–1.08) for napping sometimes and 1.11 (1.07–1.15) for napping
usually vs rarely/never (Supplementary Figure 1).
We also estimated RRs for the dichotomous comparison of
women who reported napping either sometimes or usually vs those
who reported napping rarely or never, in each 2-year period of
follow-up after baseline (Figure 1). Results for breast cancer were
considered separately from cancers at other sites. Relative risks
declined significantly during follow-up both for breast cancer
(P¼ 0.001 for trend) and for other cancers (P¼ 0.01 for trend).
The RR of breast cancer was highest in the first 4 years of follow-up
(combined RR¼ 1.10, 95% CI 1.06–1.15, for napping sometimes or
usually vs rarely/never, in the first 4 years after baseline), but after
4 or more years of follow-up (average 7.6 years), there was no
significant excess risk associated with more frequent napping
(combined RR¼ 1.00, 0.96–1.05). A similar pattern was observed
in the RRs for invasive cancers other than breast cancer
(RR¼ 1.12, 1.08–1.15, in the first 4 years after baseline, and
RR¼ 1.04, 1.01–1.07, 4 or more years after baseline). In detailed
investigations by cancer site, associations during the first 4 years
after baseline were attenuated 4 or more years after baseline,
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Figure 1 RRs of breast cancer and any other invasive cancer for women
who nap sometimes or usually vs those who nap rarely/never, by period of
follow-up.
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despite similar case numbers in each period, and became
nonsignificant for all sites except the lung and endometrium
(Figure 2). Because an association with liver cancer mortality was
previously reported (Suzuki, 2007), we also investigated the
association of napping with liver cancer incidence. Relative risks
were 1.19 (0.84–1.69) and 1.09 (0.82–1.46), respectively, in the first
4 years after baseline and 4 or more years after baseline, not
replicating the previous finding.
DISCUSSION
Pre-clinical disease is a likely explanation for the observed decline
over time in the risk of cancer associated with daytime napping.
Because good repeatability of self-reported napping behaviour was
maintained over time, regression dilution due to reporting errors
or changes in napping behaviours would not be expected to
produce the observed attenuations of RRs during follow-up. It is
unknown whether associations of cancer risk with other sleep or
fatigue-related behaviours might also reflect pre-clinical disease.
The main strengths of this study are its large size and
prospective design, the virtually complete follow-up for incident
cancers, and the ability to examine the repeatability of reported
daytime napping several years later. For cancers other than breast
cancer, however, follow-up may not be long enough to rule out a
residual effect of pre-clinical disease, because some cancers
present with specific symptoms later than others. It is also
impossible to rule out residual confounding in reported RRs, and
in particular we were unable to investigate potential confounding
factors related to sleep or napping behaviours, such as chronotype
and employment in shift work.
In summary, there was an association between more frequent
daytime napping and a slight increased risk of breast and some
other cancers in the first 4 years of follow-up in this cohort. This is
consistent with napping being a marker of pre-clinical disease in
some women.
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